Abstract
Since highly active antiretroviral therapy (HAART) was introduced a decade ago, it has been shown to be effective in keeping HIV-1 replication under control. Nevertheless, it is also known that HAART has certain limitations, such as its inability to completely inhibit the viral replication that maintains virus reservoirs, its high toxicity when the treatment is maintained for long periods of time, and the appearance of viral resistance to the therapy. These limitations have led to the introduction of structured treatment interruption (STI) of antiretroviral therapy, the principle of which is to reduce the clinical complications of HAART, and hypothetically to boost the cellular immune response of the patient host. The aim of this study was to analyze for the first time the impact of STI on the innate immune system. Specifically, we analyzed NK cells and their regulatory receptors (KIRs, NKG2, NCRs, and ILTs) and the cytokines that might control the NK response. Six months after the initiation of STI, the results revealed in most patients a significant increase in NK cells expressing ILT2 and NKp46 receptors. Slight or no changes were observed in other parameters studied, either during interruption or when HAART was reintroduced...Continue Reading
References
Apr 16, 1998·The Journal of Infectious Diseases·M BarcovaM P Dierich
Dec 29, 1998·Immunology Today·A RubartelliM R Zocchi
Mar 18, 2000·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·N Clumeck, S De Wit
Jun 21, 2001·AIDS·F GarcíaJ M Gatell
Apr 30, 2002·Current Opinion in Infectious Diseases·V Miller
Jun 25, 2002·Journal of Clinical Immunology·Raquel TarazonaJose Peña
Oct 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ume L Abbas, John W Mellors
Dec 5, 2002·Current Molecular Medicine·Daniel Scott-Algara, Pascale Paul
Feb 7, 2003·Current Medicinal Chemistry·L BelmonteB H Ruibal-Ares
Mar 21, 2003·Proceedings of the National Academy of Sciences of the United States of America·Roberta CastriconiAlessandro Moretta
Aug 26, 2003·European Journal of Immunology·Andrea De MariaLorenzo Moretta
Nov 7, 2003·Human Immunology·Almudena CabelloJosé Peña
Nov 25, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Daniel Scott-AlgaraGianfranco Pancino
Dec 3, 2003·Proceedings of the National Academy of Sciences of the United States of America·Domenico MavilioAnthony S Fauci
Mar 17, 2004·Viral Immunology·Alicja Wiercińska-DrapaloDanuta Prokopowicz
Mar 20, 2004·The Journal of Infectious Diseases·S KottililA S Fauci
Feb 9, 2005·Proceedings of the National Academy of Sciences of the United States of America·Domenico MavilioAnthony S Fauci
Oct 18, 2005·AIDS·Christopher M MelaMartin R Goodier
Oct 20, 2005·The Journal of Infectious Diseases·Adrienne R ToulsonJulio S G Montaner
Oct 22, 2005·Nature Reviews. Immunology·Anthony S FauciShyam Kottilil
Dec 20, 2005·Viral Immunology·Alejandro VallejoManuel Leal
Feb 8, 2006·Health & Social Care in the Community·Helen Spandler, Nicola Vick
Jun 9, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Sonia Molina-PineloManuel Leal
Aug 8, 2006·Lancet·Jintanat AnanworanichUNKNOWN Swiss HIV Cohort Study
Sep 5, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Jody LawrenceJohn D Baxter
Citations
Apr 11, 2009·Current HIV/AIDS Reports·Kenneth A Lichtenstein
Jan 11, 2011·International Immunology·Federica BozzanoAndrea De Maria
Jan 12, 2012·Viral Immunology·José PeñaUNKNOWN Dc2-Manon07 Vaccine Research Group
Mar 19, 2019·AIDS·Jillian S Y LauJames H McMahon